4D Molecular Therapeutics, Inc. ·
FDMT 8-K 2026-09-28
4D Molecular Therapeutics, Inc. (FDMT) 8-K dated 2026-09-28 — accession 0001193125-26-403424.
4D Molecular Therapeutics, Inc. (FDMT) is a biotechnology company listed on US.
4D Molecular Therapeutics, Inc. filed a 8-K on 2026-09-28. Accession 0001193125-26-403424.
This 8-K covers: Other events (Item 8.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported FDMT revenue for 2025-12-31 was $85.2M. Net income was -$140.1M. Revenue was up 230194.6% from 2024-12-31 to 2025-12-31. FDMT currently screens at market cap $518.1M.
Not investment advice. The FDMT SEC hub lists recent forms. The stock page is the research view.